(Q44794025)

English

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy.

scientific article published in March 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

author name string

F W N M Wit

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

P Reiss

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

J K M E Schattenkerk

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

M E van der Ende

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

M M E Schneider

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

J W Mulder

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

P H J Frissen

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

F de Wolf

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

J M A Lange

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

publication date

1 March 2004

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

74-81

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15012645%20AND%20SRC:MED&resulttype=core&format=json

25 December 2019

Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Adverse effects of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group P

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Immunologic reconstitution after 1 year of highly active antiretroviral therapy, with or without protease inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Induction of apoptosis by a nonnucleoside human immunodeficiency virus type 1 reverse transcriptase inhibitor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Differences in cellular activation and apoptosis in HIV-infected patients receiving protease inhibitors or nonnucleoside reverse transcriptase inhibitors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection--correlation with clinical progression, viral load, and loss of humoral immunity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Prevalence and predictive value of intermittent viremia with combination hiv therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Stopping primary prophylaxis in HIV-1-infected patients at high risk of toxoplasma encephalitis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Discontinuation of Secondary Prophylaxis againstPneumocystis cariniiPneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Discontinuation of prophylaxis against Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1293.2004.00188.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44794025&oldid=1364924677"